Talaris Therapeutics

GPTKB entity

Statements (19)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Takeda_Pharmaceuticals_International_AG
gptkbp:aims_to treat autoimmune diseases
treat organ transplant rejection
gptkbp:ceo gptkb:Michael_A._Mc_Garrity
gptkbp:clinical_trial ongoing
gptkbp:collaborates_with research institutions
gptkbp:develops Talaris Therapeutics' lead product candidate
gptkbp:focuses_on gptkb:drug
gptkbp:founded gptkb:2018
gptkbp:headquarters gptkb:Nashville,_Tennessee
https://www.w3.org/2000/01/rdf-schema#label Talaris Therapeutics
gptkbp:investment venture capital firms
gptkbp:partnerships various academic institutions
gptkbp:research_focus immune tolerance
gptkbp:stock_exchange gptkb:battle
gptkbp:technology Talaris' proprietary technology platform
gptkbp:website www.talaristx.com